Edition:
United Kingdom

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

5.45USD
16 Feb 2018
Change (% chg)

$-0.01 (-0.18%)
Prev Close
$5.46
Open
$5.46
Day's High
$5.48
Day's Low
$5.34
Volume
541
Avg. Vol
8,120
52-wk High
$10.90
52-wk Low
$4.42

Latest Key Developments (Source: Significant Developments)

Therapix Biosciences Announces Expansion Into Precision Medicine Through New Fully-Owned Subsidiary
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES ANNOUNCES EXPANSION INTO PRECISION MEDICINE THROUGH NEW FULLY-OWNED SUBSIDIARY AND PROVIDES CORPORATE UPDATE TODAY AT THE BIOTECH SHOWCASE™ 2018.THERAPIX BIOSCIENCES LTD - ‍EXPANDING INTO PRECISION MEDICINE THROUGH A NEW FULLY-OWNED SUBSIDIARY IN ORDER TO DEVELOP "NOVEL SOLUTIONS FOR PAIN"​.  Full Article

Therapix Biosciences and Co's CFO Entered Into A "Mutually-Amicable" Separation Agreement
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Therapix Biosciences Ltd ::THERAPIX BIOSCIENCES SAYS CO AND CFO JOSH BLACHER ENTERED INTO A "MUTUALLY-AMICABLE" SEPARATION AGREEMENT ON DECEMBER 19 - SEC FILING.THERAPIX BIOSCIENCES SAYS IS IN THE PROCESS OF SEARCHING FOR A NEW CHIEF FINANCIAL OFFICER.  Full Article

Therapix Biosciences Q3 loss per share $0.30
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Therapix Biosciences Ltd : :Therapix Biosciences reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.30.Therapix Biosciences Ltd - ‍cash totaled $10.7 Million as of September 30, 2017, compared to $11.8 million as of June 30, 2017​.  Full Article

Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Therapix Biosciences Ltd :Therapix Biosciences and Assuta Medical Center to initiate clinical trial in obstructive sleep apnea.  Full Article

Therapix biosciences says CEO Dr. Haber resigned
Wednesday, 24 May 2017 

May 24 (Reuters) - Therapix Biosciences Ltd :Therapix biosciences announces ceo change.Says ceo dr haber resigned.Therapix biosciences ltd - board of directors is undertaking a search to identify a permanent, u.s. Based chief executive officer.  Full Article

Therapix Biosciences files application with FDA for an Orphan designation for Tourette's Syndrome drug
Wednesday, 15 Jun 2016 

: Therapix biosciences ltd says estimates that an initial clinical trial will begin in h2/2016 .Therapix biosciences filed an application with the fda to approve an "orphan" designation for the drug developed based on the entourage technology for treating tourette's syndrome.  Full Article

BRIEF-Therapix Biosciences Expects To Test THX-110 In Early Study In Q2

* THERAPIX BIOSCIENCES LTD - EXPECT TO EVALUATE THX-110 IN A PHASE IIB CLINICAL STUDY IN Q2 OF 2018